Novel Approaches to Thyroid Cancer Treatment and Response Assessment.
Novel Approaches to Thyroid Cancer Treatment and Response Assessment.
复制标题
DOI：
10.1053/j.semnuclmed.2015.10.010
复制
发表时间：
2016-03
影响因子：
4.9
通讯作者：
Schöder H
中科院分区：
文献类型：
--
作者：
Grewal RK;Ho A;Schöder H
甲状腺癌的发病率一直在上升。病理学上具有中或高风险特征的高分化甲状腺肿瘤的甲状腺全切除术后，放射性碘仍然是甲状腺残留消融和转移性疾病治疗的标准疗法之一。SPECT/CT是一种相对较新的检查方法，通过改变甲状腺癌患者的风险分层，在治疗后环境中发挥着关键作用。在放射性碘治疗失败的情况下，其他方式，如FDG PET/CT已被证明可以提供代谢活动和外部射束放射治疗方面的预后信息，从而在疾病管理中发挥作用。使用I-124 PET/CT评估了新的再分化药物的作用。
The incidence of thyroid cancer has been on the rise. After total thyroidectomy of well differentiated thyroid tumors with intermediate or high-risk features on pathology, radioiodine remains one of the mainstays as the standard therapy for thyroid remnant ablation as well as treatment of metastatic disease. SPECT/CT, a relatively newer modality, has shown to play a pivotal role predominantly in the post-therapy setting by changing the risk stratification of patients with thyroid cancer. In the case of radioiodine failure, other modalities such as FDG PET/CT have been shown to provide prognostic information in terms of metabolic activity and external beam radiation therapy, thereby playing a role in disease management. The role of newer redifferentiation drugs has been evaluated with the use of I-124 PET/CT.